Publication: Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity
3
Issued Date
2010-01-10
Resource Type
ISSN
14740338
Other identifier(s)
2-s2.0-74349097462
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Expert Opinion on Drug Safety. Vol.9, No.1 (2010), 39-53
Suggested Citation
Ticha Limsuwan, Mariana C. Castells Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opinion on Drug Safety. Vol.9, No.1 (2010), 39-53. doi:10.1517/14740330903446936 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/29798
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity
Author(s)
Other Contributor(s)
Abstract
Importance of the field: The incidence of hypersensitivity reactions (HSRs) to chemotherapy agents has increased because of increasing number of cancer survivors are exposed to repeated courses of sensitizing agents. Replacement with an alternative chemotherapy regimen is often limited by tumor sensitivity. Rapid desensitization offers an effective mean to allow continuation of the treatment to which patients have presented HSRs. Areas covered in this review: We review the methods, outcome and safety of the rapid desensitization protocol developed at Brigham and Women's Hospital, Harvard Medical School Affiliate, based on our recent publication "'Hypersensitivity reactions to chemotherapy: outcome and safety of rapid desensitization in 413 cases". Literature search was conducted through Medline (from January 1976 to September 2009), using PubMed. What the reader will gain: The article will give insight to clinical manifestations of immediate HSR to various chemotherapy agents and their presumably different immunopathomechanism. Risk assessment, including skin testing in those presented HSRs to platins and details on rapid desensitization process and its pitfalls will be discussed. Take home message: Standa"rd protocol of rapid desensitization, administering under multidisciplinary team approach, is safe and effective in overcoming immediate HSRs to platins, taxanes, doxorubicin and rituximab via both intravenous and intraperitoneal routes. © 2010 Informa UK Ltd ISSN.